Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atherosclerosis (IMPRESS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01330602 |
Recruitment Status
: Unknown
Verified October 2013 by National University Hospital, Singapore.
Recruitment status was: Recruiting
First Posted
: April 7, 2011
Last Update Posted
: October 10, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Atherosclerotic Cardiovascular Disease Cardiovascular Disease | Behavioral: IMPRESS intervention | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1310 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Screening |
Official Title: | Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atherosclerosis: The IMPRESS Study- A Multi-centre, Randomised Controlled Trial |
Study Start Date : | May 2010 |
Estimated Primary Completion Date : | December 2013 |
Estimated Study Completion Date : | December 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Lifestyle counseling
All participants randomised into the IMPRESS Intervention group will undergo tailored health profiling.This individual assessment will be carried out within the clinic setting. The key elements of the IMPRESS intervention include:
|
Behavioral: IMPRESS intervention
The key elements of the IMPRESS intervention include:
Other Names:
|
No Intervention: Usual care arm
Usual Care Following the assessment of absolute cardiovascular risk, usual care participants will be provided a report outlining areas in which improvements could be made for the prevention of atherosclerotic burden. No restrictions will be made in respect to usual care management. As such, the prescription of standard medications for primary prevention of atherosclerotic burden based on individual risk factors is anticipated in 20-30% of usual care participants. At 18 months and three years those in the usual care arm will be invited to undergo repeat CIMT measurements, pathology, absolute risk score calculation and health-related questionnaires as part of the structured study follow-up |
- Change in CIMT from baseline to three years [ Time Frame: 3 years ]
CIMT will be used as a validated surrogate of atherosclerotic status and future cardiovascular events in this study.
As such, this study will use CIMT (as both a delineator of risk and in the primary endpoint), a marker of atherosclerotic burden (the disease process rather than a surrogate), to address the unresolved issue about how to most efficiently manage intermediate risk subjects with a family history of premature atherosclerosis
- i) Plaque length (carotid artery) ii) Internal CIMT iii) General health and well being iv) Mental health v) Health care costs vi) Modifiable risk factors [ Time Frame: 3 years ]In intermediate risk, first-degree relatives (i.e. mother, father, brother or sister) of individuals with premature atherosclerosis, a CIMT-targeted DMP for primary prevention (the IMPRESS intervention) incorporating more intensive non-pharmacological and pharmacological management, provides no better reduction of atherosclerotic burden (as determined by the change in CIMT from baseline to follow-up completion) than usual health care management during three years follow-up.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Have a first-degree relative (i.e. a mother, father, brother or sister) with premature (onset <65 years of age) atherosclerosis. This includes coronary artery disease/acute myocardial infarction, non-haemorrhagic stroke and peripheral vascular disease.
- Are classified as "intermediate risk" of experiencing a cardiovascular event in the next 5 years as determined via the Framingham Risk Equation 7, 22
- Live within a geographically accessible area for follow-up (i.e. within a 40km radius of the study centre)
- Are living independently in the community or their own home
- Are able and willing to provide written informed consent to participate in the study (this includes the ability to understand and speak English fluently and that the patient is mentally competent)
Exclusion Criteria:
- Pre-existing atherosclerotic disease
- Have been diagnosed with Type 1 or Type 2 Diabetes Mellitus
- Have contraindications to the use of statin medications (includes pregnancy and breastfeeding)
- Unable to provide written informed consent to participate in this study
- Have a terminal malignancy requiring palliative care, or limited life expectancy or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
- Participating in another clinical research trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01330602
Contact: Khong Y Tang, Ms | 65167456 | nurkyt@nus.edu.sg | |
Contact: Kee B Leng, Mdm | 65167456 | nurkblb@nus.edu.sg |
Singapore | |
National University Hospital | Recruiting |
Singapore, Singapore, 119228 | |
Contact: Ling L Hsi, Assoc Prof 67725283 mdcllh@nus.edu.sg | |
Novena heart Centre | Recruiting |
Singapore, Singapore, 307506 | |
Contact: Raymond Lee, Dr 6397-2004 appt@novenaheartcentre.com.sg | |
Tan Tock Seng Hospital | Recruiting |
Singapore, Singapore, 308433 | |
Contact: Poh Shuan Daniel Yeo, MBBS,MRCP(UK),FRCP(Edin),FACC +6563577831 | |
Principal Investigator: Poh Shuan Daniel Yeo, MBBS,MRCP(UK),FRCP(Edin),FACC |
Principal Investigator: | Desley G HEGNEY, Professor | National University Health system, NUS |
Responsible Party: | National University Hospital, Singapore |
ClinicalTrials.gov Identifier: | NCT01330602 History of Changes |
Other Study ID Numbers: |
DSRB-C/10/005 |
First Posted: | April 7, 2011 Key Record Dates |
Last Update Posted: | October 10, 2013 |
Last Verified: | October 2013 |
Additional relevant MeSH terms:
Cardiovascular Diseases Atherosclerosis Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |